No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CABA250117C2000
- 0.00
- 0.000.00%
15min DelayNot Open Jan 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-3.61%PremiumJan 17, 2025Expiry Date0.08Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Cabaletta Bio Advances Clinical Trials With Lonza Partnership
Express News | Cabaletta Bio Inc: Unaudited Cash and Cash Equivalents as of Dec 31, 2024 Was $164 Mln
Cabaletta Bio Outlines 2025 Milestones, Plans Meeting With FDA On Rese-cel Trial Designs, Favorable Safety With 90% Patients Showing No Significant Side Effects, First Enrollments In RESET-PV And RESET-Myositis Trials, IND Cleared For RESET-MS With...
Express News | Cabaletta Bio Inc - Caballetta to Meet FDA on Rese-Cel Trial Designs in 1H25
Express News | Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6